Evidence map›Paper›PMID 23388133›Full record

ArticleBMC cancer2013

Rac3 induces a molecular pathway triggering breast cancer cell aggressiveness: differences in MDA-MB-231 and MCF-7 breast cancer cell lines.

Caroline Gest, Ulrich Joimel, Limin Huang, Linda-Louise Pritchard, Alexandre Petit, Charlène Dulong, Catherine Buquet, Chao-Quan Hu, Pezhman Mirshahi, Marc Laurent and 8 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in BMC cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 119 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. UHPLC-QTOF-MS Profiling of Chemical Constituents in POW9International journal of molecular sciences · 2026
    Article
  13. Article
  14. Site-selective arylations of nature-inspired flavonoids or steroidal phenolsJournal of enzyme inhibition and medicinal chemistry · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 1 country.

Caroline GestLaboratoire MERCI - EA3829, Faculté de Médecine et de Pharmacie, Université de Rouen, Rouen, France. caroline.gest@yahoo.fr
Ulrich Joimel
Limin Huang
Linda-Louise Pritchard
Alexandre Petit
Charlène Dulong
Catherine Buquet
Chao-Quan Hu
Pezhman Mirshahi
Marc Laurent
Françoise Fauvel-Lafève
Lionel Cazin
Jean-Pierre Vannier
He Lu
Jeannette Soria
Hong Li
Rémi Varin
Claudine Soria
Université de Rouen Normandie · FRInserm · FRCentre National de la Recherche Scientifique · FRHôtel-Dieu de Paris · FRUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRho GTPases are involved in cellular functions relevant to cancer. The roles of RhoA and Rac1 have already been established. However, the role of Rac3 in cancer aggressiveness is less well understood.

methodsThis work was conducted to analyze the implication of Rac3 in the aggressiveness of two breast cancer cell lines, MDA-MB-231 and MCF-7: both express Rac3, but MDA-MB-231 expresses more activated RhoA. The effect of Rac3 in cancer cells was also compared with its effect on the non-tumorigenic mammary epithelial cells MCF-10A. We analyzed the consequences of Rac3 depletion by anti-Rac3 siRNA.

resultsFirstly, we analyzed the effects of Rac3 depletion on the breast cancer cells' aggressiveness. In the invasive MDA-MB-231 cells, Rac3 inhibition caused a marked reduction of both invasion (40%) and cell adhesion to collagen (84%), accompanied by an increase in TNF-induced apoptosis (72%). This indicates that Rac3 is involved in the cancer cells' aggressiveness. Secondly, we investigated the effects of Rac3 inhibition on the expression and activation of related signaling molecules, including NF-κB and ERK. Cytokine secretion profiles were also analyzed. In the non-invasive MCF-7 line; Rac3 did not influence any of the parameters of aggressiveness.

conclusionsThis discrepancy between the effects of Rac3 knockdown in the two cell lines could be explained as follows: in the MDA-MB-231 line, the Rac3-dependent aggressiveness of the cancer cells is due to the Rac3/ERK-2/NF-κB signaling pathway, which is responsible for MMP-9, interleukin-6, -8 and GRO secretion, as well as the resistance to TNF-induced apoptosis, whereas in the MCF-7 line, this pathway is not functional because of the low expression of NF-κB subunits in these cells. Rac3 may be a potent target for inhibiting aggressive breast cancer.

Indexed as

ApoptosisBreast NeoplasmsCell AdhesionCell MovementCell ShapeCell SurvivalCollagenCytokinesExtracellular Signal-Regulated MAP KinasesFemaleHumansMatrix Metalloproteinase 9MCF-7 CellsNeoplasm InvasivenessNF-kappa Brac GTP-Binding ProteinsCollagenCytokinesExtracellular Signal-Regulated MAP KinasesMatrix Metalloproteinase 9MMP9 protein, humanNF-kappa BRAC3 protein, humanrac GTP-Binding ProteinsrhoA GTP-Binding ProteinRHOA protein, humanTumor Necrosis Factor-alpha

Identifiers

PMID23388133
PMCPMC3576359
OpenAlexW2130326989

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.